Treatment of premature ovarian failure with hormone replacement therapy or combined oral contraceptive pill

Submission date Recruitment status [X] Prospectively registered 15/01/2009 No longer recruiting [X] Protocol [] Statistical analysis plan Registration date Overall study status 26/01/2009 Completed [X] Results [] Individual participant data Last Edited Condition category Nutritional, Metabolic, Endocrine 28/08/2018

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Janice Rymer

Contact details

Department of Women's Health Tenth Floor North Wing St Thomas' Hospital London United Kingdom SE1 7EH

Additional identifiers

Clinical Trials Information System (CTIS) 2008-002599-86

Protocol serial number N/A

Study information

Scientific Title

A prospective open randomised controlled trial of women diagnosed with premature ovarian failure (POF) to investigate the effects of active treatment with hormone replacement therapy (HRT) or combined oral contraceptive pill (COCP), and observation of patients who choose to have no treatment, on bone density, markers of cardiovascular disease, markers of bone metabolism, menopausal symptoms, quality of life, depression score, sexual function and ovarian function over two years

Study objectives

It is assumed that bone loss will occur at the normal post-menopausal rate in the no treatment group and that bone mass will be preserved and will be equal in the two treatment groups (hormone replacement therapy [HRT] and combined oral contraceptive pill [COCP]).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Guy's Research Ethics Committee, approved on 18/12/2008 (ref: 08/H0804/140)

Study design

Prospective open randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Premature ovarian failure

Interventions

Participants will be asked whether they wish to receive treatment or prefer not to receive treatment. Those who choose to be in the active treatment group will be randomised to take either Nuvelle® or Microgynon® 30 for two years. Nuvelle® is oestradiol 2 mg once a day for 16 days then oestradiol 2 mg and levonorgestrel 75 mcg for 16 days on a cyclical basis. Microgynon® 30 is ethinylestradiol 30 mcg and levonorgestrel 150 mcg daily for 21 days followed by a 7 day pill-free break on a cyclical basis.

The participants who decide not to receive treatment will be followed-up for two years.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Nuvelle®, Microgynon®

Primary outcome(s)

Bone mineral density at the lumbar spine and hip, assessed at 0, 6, 12 and 24 months.

Key secondary outcome(s))

- 1. Serum markers of bone metabolism, assessed at 0, 6, 12 and 24 months
- 2. Menopausal symptom scores, assessed at 0, 3, 6, 12, 18, 24 months
- 3. Depression score, assessed at 0, 3, 6, 12, 18, 24 months
- 4. Sexual function, assessed at 0, 3, 6, 12, 18, 24 months
- 5. Quality of life, assessed by SF-36® Health Survey at 0, 3, 6, 12, 18, 24 months
- 6. Serum markers of cardiovascular disease (lipid profile, C reactive protein [CRP]), assessed at 0,
- 6, 12 and 24 months
- 7. Ovarian function markers (anti-Mullerian hormone [AMH] and inhibin-B), assessed at 0, 6, 12, 24 months
- 8. Ovarian volume and antral follicle count, assessed by ultrasound at 0, 6, 12, 24 months

Completion date

01/09/2011

Eligibility

Key inclusion criteria

- 1. Age 18-44 years
- 2. Women with a diagnosis of premature ovarian failure (POF) within the last 36 months (with documented follicle-stimulating hormone [FSH] level >30 IU on 2 occasions 4-8 weeks apart)
- 3. Ability to understand English
- 4. Written informed consent for participation in the trial
- 5. Not taking hormone medication (HRT/COCP/"natural" preparations) for 2 months prior to commencement in the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

44 years

Sex

Female

Key exclusion criteria

- 1. Age less than 18 or over 45 years
- 2. Current desire for pregnancy is an exclusion criterion from the active treatment group (as she may be randomised to take COCP). However, she could elect to take part in the no treatment

group.

- 3. Women with absolute contraindications to hormone treatment will be excluded from the active treatment group (i.e. personal history of thromboembolic disease, oestrogen dependent malignancies, and personal history of focal migraine)
- 4. Women taking medication for high cholesterol or found to have raised cholesterol levels on initial assessment
- 5. Untreated thyroid disease

Date of first enrolment 01/03/2009

Date of final enrolment 01/09/2011

Locations

Countries of recruitmentUnited Kingdom

England

Study participating centre
Department of Women's Health
London
United Kingdom
SE1 7EH

Sponsor information

Organisation

King's College London (UK)

ROR

https://ror.org/0220mzb33

Funder(s)

Funder type

Charity

Funder Name

Wellcome Trust (UK), Research Training Fellowship, decision expected in April 2009 (ref: 10092)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created Date adde	ed Peer reviewed	? Patient-facing?
Results article	results	01/09/2016	Yes	No
Protocol article	protocol	01/03/2010	Yes	No
HRA research summary		28/06/202	23 No	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/202	25 No	Yes